Education
About Us
Working with TipRanks
Follow Us
Eton Pharmaceuticals Inc (ETON)
NASDAQ:ETON
ETON Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.03 - $18.41
Previous CloseN/A
Volume127.06K
Average Volume (3M)244.79K
Market Cap
$348.09M
Enterprise Value$143.37M
Total Cash (Recent Filing)$13.16M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.82
Next Earnings
May 08, 2025EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding26,817,535
10 Day Avg. Volume261,893
30 Day Avg. Volume244,787
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.78
Price to Cash Flow (P/CF)-124.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.12
Enterprise Value/Ebitda-83.79
Forecast
1Y Price Target
$28.50Price Target Upside119.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Market ExpansionIf successful in obtaining a label expansion for Increlex, the eligible patient population could grow from approximately 200 to 1,000, significantly boosting potential revenue.
Product LaunchEton Pharmaceuticals is on track to launch ET-400, a hydrocortisone oral solution, which is expected to address issues with the current granule texture and drive robust adoption.
Revenue GrowthManagement projects peak combined revenue of ET-400 and ALKINDI SPRINKLE to exceed $50 million annually.
Strategic AcquisitionsRecent acquisitions of Galzin, Increlex, and Amglidia are expected to be major revenue drivers in the near and long term.
Bears Say
Operational ChallengesThe reaffirmation of Galzin's re-launch strategy and ET-400 guidance suggests continued readiness for the market, minimizing the impact of the launch delay.
Regulatory ChallengesThe 3-month PDUFA delay is unrelated to clinical or manufacturing issues, which suggests no significant setbacks for Eton Pharmaceuticals.
---
Ownership Overview
15.28% Insiders
7.05% Mutual Funds
35.95% Other Institutional Investors
37.64% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ETON FAQ
What was Eton Pharmaceuticals Inc’s price range in the past 12 months?
Eton Pharmaceuticals Inc lowest stock price was $3.03 and its highest was $18.41 in the past 12 months.
What is Eton Pharmaceuticals Inc’s market cap?
Eton Pharmaceuticals Inc’s market cap is $348.09M.
When is Eton Pharmaceuticals Inc’s upcoming earnings report date?
Eton Pharmaceuticals Inc’s upcoming earnings report date is May 08, 2025 which is in 36 days.
How were Eton Pharmaceuticals Inc’s earnings last quarter?
Eton Pharmaceuticals Inc released its earnings results on Mar 18, 2025. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of -$0.003 by -$0.017.
Is Eton Pharmaceuticals Inc overvalued?
According to Wall Street analysts Eton Pharmaceuticals Inc’s price is currently Undervalued.
Does Eton Pharmaceuticals Inc pay dividends?
Eton Pharmaceuticals Inc does not currently pay dividends.
What is Eton Pharmaceuticals Inc’s EPS estimate?
Eton Pharmaceuticals Inc’s EPS estimate is 0.03.
How many shares outstanding does Eton Pharmaceuticals Inc have?
Eton Pharmaceuticals Inc has 26,817,535 shares outstanding.
What happened to Eton Pharmaceuticals Inc’s price movement after its last earnings report?
Eton Pharmaceuticals Inc reported an EPS of -$0.02 in its last earnings report, missing expectations of -$0.003. Following the earnings report the stock price went down -3.99%.
Which hedge fund is a major shareholder of Eton Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ETON
---
Eton Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.50 (119.57% Upside)
$28.50 (119.57% Upside)
Blogger Sentiment
Bullish
ETON Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $79.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
246.13%
12-Months-Change
Fundamentals
Return on Equity
-19.16%
Trailing 12-Months
Asset Growth
139.83%
Trailing 12-Months
Company Description
Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
---
ETON Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
Eton Pharmaceuticals reported strong revenue growth and strategic acquisitions, with a clear path to increasing its market presence. However, challenges remain in managing SG&A expenses and overcoming historical access issues for some products.Read More>---
ETON Stock 12 Month Forecast
Average Price Target
$28.50
▲(119.57% Upside)
Technical Analysis
Heron Therapeutics
―
Benitec Biopharma
―
Mereo Biopharma Group Plc
―
Tectonic Therapeutic
―
AbSci
―
Best Analysts Covering ETON
1 Year
1 Year Success Rate
7/9 ratings generated profit
1 Year Average Return
+97.50%
reiterated a buy rating yesterday
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +97.50% per trade.
---